Suppr超能文献

商陆有丝分裂原刺激的人淋巴细胞与LICR - 2(HMY2)融合,产生对人乳腺癌和恶性黑色素瘤有反应的产生单克隆IgG抗体的人 - 人杂交瘤。

Pokeweed mitogen-stimulated human lymphocytes fused to LICR-2 (HMY2) generate human-human hybridomas producing monoclonal IgG antibodies reactive to human breast carcinoma and malignant melanoma.

作者信息

Martin R F, Kisor R, Schroer D, Eichler G, Filaccio M L

机构信息

Wright State University School of Medicine, Hamilton, Ohio.

出版信息

Hum Antibodies Hybridomas. 1990;1(3):154-9.

PMID:2103359
Abstract

Human-human hybridomas were generated using pokeweed mitogen-stimulated lymphocytes from the regional lymph nodes of cancer patients by fusion to the LICR-2 human myeloma cell line. A total of 35 fusions, using the regional lymph node lymphocytes of cancer patients, resulted in hybrid growth in 23% of wells plated with 21 IgG ELISA positive clones, 6 of which have maintained stable human monoclonal antibody production. Mononuclear cells were separated on Ficoll-Paque and grown for 3-4 days in 1% pokeweed mitogen and fused to the LICR-2 human myeloma cell line. Human-human hybridoma producing membrane reactive IgG antibodies have been isolated and react to the following cancers: breast; melanoma. Twenty-seven fusions from 8 breast carcinoma patients resulted in 13 ELISA positive IgGs, 3 of which were stable after cloning. A total of 5,071 wells were plated after polyethylene glycol fusion with resultant hybrid growth in 1210 wells (24% hybrid growth) after hypoxanthine-aminopterin-thymidine selection. In 8 fusions using regional lymph node lymphocytes of other types of cancer, including 6 fusions using lymphocytes from malignant melanoma patients, there were 1,580 wells plated with positive growth in 20% of the wells (311 wells). Of these, 8 clones were ELISA positive and 3 stable clones all producing IgG anti-melanoma antibody were isolated. The overall hybrid frequency was 43 x 10(-7) fused lymphocytes (39 x 10(-7) non-breast and 45 x 10(-7) breast). A total of 21 IgG-producing clones were identified to crude membranes of allogeneic tumor cell lines and stable antibody production was achieved for 6 (29% stable clones).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

利用来自癌症患者区域淋巴结的经商陆有丝分裂原刺激的淋巴细胞与LICR - 2人骨髓瘤细胞系融合,产生了人 - 人杂交瘤。使用癌症患者区域淋巴结淋巴细胞进行了总共35次融合,在接种的孔中有23%出现杂交生长,得到21个IgG ELISA阳性克隆,其中6个已维持稳定的人单克隆抗体产生。单核细胞在Ficoll - Paque上分离,并在1%商陆有丝分裂原中培养3 - 4天,然后与LICR - 2人骨髓瘤细胞系融合。已分离出产生膜反应性IgG抗体的人 - 人杂交瘤,它们对以下癌症有反应:乳腺癌;黑色素瘤。来自8例乳腺癌患者的27次融合产生了13个ELISA阳性IgG,其中3个在克隆后稳定。聚乙二醇融合后接种了总共5071个孔,次黄嘌呤 - 氨基蝶呤 - 胸腺嘧啶核苷选择后,1210个孔中有杂交生长(24%杂交生长)。在使用其他类型癌症区域淋巴结淋巴细胞的8次融合中,包括使用恶性黑色素瘤患者淋巴细胞的6次融合,接种了1580个孔,20%的孔有阳性生长(311个孔)。其中,8个克隆为ELISA阳性,分离出3个均产生IgG抗黑色素瘤抗体的稳定克隆。总体杂交频率为43×10⁻⁷融合淋巴细胞(非乳腺癌为39×10⁻⁷,乳腺癌为45×10⁻⁷)。总共鉴定出21个产生IgG的克隆与异基因肿瘤细胞系的粗膜反应,6个实现了稳定抗体产生(29%稳定克隆)。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验